Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - olmesartaanmedoksomiil+amlodipiin - õhukese polümeerikattega tablett - 40mg+5mg 30tk; 40mg+5mg 100tk; 40mg+5mg 28tk; 40mg+5mg 250tk; 40mg+5mg 14tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - olmesartaanmedoksomiil+amlodipiin - õhukese polümeerikattega tablett - 40mg+10mg 28tk; 40mg+10mg 14tk; 40mg+10mg 30tk; 40mg+10mg 98tk; 40mg+10mg 10tk; 40mg+10mg 90tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - olmesartaanmedoksomiil+amlodipiin - õhukese polümeerikattega tablett - 20mg+5mg 14tk; 20mg+5mg 56tk; 20mg+5mg 100tk; 20mg+5mg 10tk; 20mg+5mg 28tk; 20mg+5mg 98tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - tsüstiline fibroos - muud hingamisteede tooted - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Eesti - eesti - Ravimiamet

institute of isotopes co. ltd. - tehneetsium(99mtc)sestamibi - radiofarmatseutiline komplekt - 1mg 6tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosupressandid - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Euroopa Liit - eesti - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland - prucalopride naatriumoktenüülsuktsinaat-tärklis - kõhukinnisus - muud ravimid kõhukinnisuse jaoks - resolor on näidustatud kroonilise kõhukinnisuse sümptomaatiliseks raviks täiskasvanutel, kellel lahustid ei suuda piisavat leevendust pakkuda.

Euroopa Liit - eesti - EMA (European Medicines Agency)

chanelle pharmaceuticals manufacturing ltd - imidaklopriid, moxidectin - antiparasitic products, insecticides and repellents, macrocyclic lactones, milbemycins - cats; dogs; ferrets - for cats suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of ear mite infestation (otodectes cynotis),• the treatment of notoedric mange (notoedres cati),• the treatment of the lungworm eucoleus aerophilus (syn. capillaria aerophila) (adults),• the prevention of lungworm disease (l3/l4 larvae of aelurostrongylus abstrusus),• the treatment of the lungworm aelurostrongylus abstrusus (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara cati and ancylostoma tubaeforme). veterinaarravimit saab kasutada kirbuallergia dermatiidi (fad) ravistrateegia osana..  for ferrets suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis).  for dogs suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of biting lice (trichodectes canis),• the treatment of ear mite infestation (otodectes cynotis), sarcoptic mange (caused by sarcoptes scabiei var. canis), demodicosis (caused by demodex canis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of circulating microfilariae (dirofilaria immitis),• the treatment of cutaneous dirofilariosis (adult stages of dirofilaria repens)• the prevention of cutaneous dirofilariosis (l3 larvae of dirofilaria repens),• the reduction of circulating microfilariae (dirofilaria repens),• the prevention of angiostrongylosis (l4 larvae and immature adults of angiostrongylus vasorum),• the treatment of angiostrongylus vasorum and crenosoma vulpis,• the prevention of spirocercosis (spirocerca lupi),• the treatment of eucoleus (syn. capillaria) boehmi (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara canis, ancylostoma caninum and uncinaria stenocephala, adults of toxascaris leonina and trichuris vulpis). veterinaarravimit saab kasutada kirbuallergia dermatiidi (fad) ravistrateegia osana..

Euroopa Liit - eesti - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - midasolaam - epilepsia - psühhoeptikumid - ravi pikaajaline, äge, convulsive krambid imikutel, väikelastel, lastel ja noorukitel (alates kolme kuu jooksul vähem kui 18 aastat). buccolam tuleb kasutada ainult vanemate / hooldajate kui patsiendil on diagnoositud, et on epilepsia. imikute vahel, kolme ja kuue kuu vanusest, tuleb ravi haigla tingimustes, kus järelevalve on võimalik ja taaselustuse seadmed on saadaval.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm ltd. - amlodipine, valsartan, hydrochlorothiazide - hüpertensioon - angiotensiin ii antagonistidega, tavaline, angiotensiin ii antagonistid, kombinatsioonid - essentsiaalse hüpertensiooni ravi täiskasvanud patsientidel, kellel on piisavat kombinatsioon amlodipiini, valsartaani ja hüdroklorotiasiidi (hct), kui kolm ühe komponendiga ravimvormid või nii asendusravi kui ka kahe komponendiga ja ühe komponendi koostise.